eTheRNA immunotherapies NV

eTheRNA immunotherapies NV, based in Belgium, is an RNA technology company focused on developing innovative therapeutic solutions, particularly in the field of immunotherapy. Founded in 2013, eTheRNA immunotherapies NV specializes in RNA technology and immunotherapy solutions. The company has received a total of 4 funding rounds, with the most recent being a Series B round in August 2022, where they raised EUR 39 million led by Novalis LifeSciences and participated by other investors including EQT Life Sciences and Omega Funds. The CEO is Bernard Sagaert, and the founder is Kris Thielemans, who has a background in RNA technology and innovation.

eTheRNA immunotherapies NV specializes in advanced RNA therapeutic solutions, including proprietary mRNA adjuvants like TriMix and TetraMix aimed at enhancing immune responses. Their products are developed for pharmaceutical and biotech companies, facilitating the advancements in RNA therapeutics in both Europe and North America. In 2023, eTheRNA reported revenue of EUR 7,356,281. 60 with an EBITDA of EUR -5,352,166.

10, indicating their financial performance amid ongoing development efforts. Following the Series B funding round in August 2022, eTheRNA plans to expand its product line with new RNA-based therapies and enhance its presence in both European and North American markets. The company aims to leverage the EUR 39 million raised to support the development of new products and strengthen collaborations with biotech partners, facilitating their entry into additional therapeutic areas by 2024.